## ARWR: Arrowhead Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 3.0% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($61.99)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition**
- Source: Business Wire | 20260106T123207 | Bullish | Relevance: 100%
- Arrowhead Pharmaceuticals announced promising interim results from clinical trials of its RNAi-based obesity candidates, ARO-INHBE and ARO-ALK7. In obese patients with type 2 diabetes, ARO-INHBE in combination with tirzepatide nearly doubled weight loss and tripled visceral, total, and liver fat reductions compared to tirzepatide alone. The data also showed robust single-agent activity and the first human demonstration of adipocyte gene target silencing with an RNAi therapeutic.

**2. Arrowhead Pharma Shares in Focus After $2.5M Insider Sale**
- Source: Eudaimonia and Co | 20260106T070907 | Somewhat-Bullish | Relevance: 100%
- Arrowhead Pharmaceuticals' Chief Medical Officer, James C. Hamilton, sold $2.5 million worth of company stock, following a similar sale by the CEO earlier this month. These sales come amidst strong stock performance due to advancements in the company's RNA interference drug pipeline and recent positive developments like the approval of REDEMPLO by Health Canada and progress in clinical trials. Analysts view these insider sales as planned under a pre-arranged trading plan rather than a negative indicator.

**3. Canada clears at-home injection for rare, painful FCS disorder**
- Source: Stock Titan | 20260105T123253 | Bullish | Relevance: 100%
- Health Canada has approved REDEMPLOâ„¢ (plozasiran) for the at-home treatment of Familial Chylomicronemia Syndrome (FCS), a rare condition causing extremely high triglyceride levels and acute pancreatitis risk. Developed by Arrowhead Pharmaceuticals, REDEMPLO is the first and only siRNA medicine approved for FCS in Canada, allowing self-administration every three months. This approval marks a significant advancement for Canadian patients with limited treatment options.

**4. Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Insider Sells 40,164 Shares of Stock**
- Source: MarketBeat | 20260106T040907 | Neutral | Relevance: 100%
- James Hamilton, an insider at Arrowhead Pharmaceuticals (NASDAQ:ARWR), sold 40,164 shares of the company's stock on January 5th. This transaction, valued at approximately $2.53 million, reduced his holding by 18.93%. The stock subsequently fell by 5.8%, though analysts maintain a "Moderate Buy" rating with an average target price of $61.89.

**5. Arrowhead Pharmaceuticals (NASDAQ:ARWR) COO Sells $3,123,503.23 in Stock**
- Source: MarketBeat | 20260106T040907 | Somewhat-Bearish | Relevance: 100%
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) COO Patrick O'Brien sold 49,493 shares of company stock for a total of $3,123,503.23 on January 5, 2026, reducing his stake by 9.44%. This transaction comes as the stock experienced a 5.8% drop on the day of the sale despite several analysts recently raising their price targets for ARWR. The company, which specializes in RNA interference therapeutics, maintains a "Moderate Buy" consensus rating from analysts.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Piper Sandler | $100 | $70 | +43% |
| 2025-12-11 | RBC Capital | $80 | $52 | +54% |
| 2025-12-09 | B of A Securiti | $81 | $62 | +31% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Piper Sandler | main | Overweight |
| 2025-12-11 | RBC Capital | main | Outperform |
| 2025-12-09 | B of A Securiti | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 9 ($0.22M) |
| Sells | 11 ($12.27M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 1 |

**Top Holders:**
- Blackrock Inc.: 14.9% (+4.1%)
- Vanguard Group Inc: 11.8% (+3.3%)
- Avoro Capital Adviso: 8.0% (+2.8%)
- State Street Corpora: 4.7% (+0.4%)
- FMR, LLC: 4.2% (+11.4%)

### Key Risks

1. Heavy insider selling: $12M sold (11 transactions in 90 days).
2. Elevated short interest (9.8%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 3 raises (avg +42%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +3.1% over 5 days suggests accumulation.

### Fundamentals

Balance sheet: strong liquidity (4.9x). Revenue declining -34% YoY, concerning. Analyst sentiment positive (3 raises, avg +42%). Insider selling cluster ($12.3M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.8B |
| Beta | 1.22 |
| 52W Range | $9.57 - $76.76 |
| Short Interest | 9.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.32 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 strengthening from -0.1% to 3.0% (+3.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.0pp (needs >4.0% for momentum thesis). MRS_5 at 4.5% confirms short-term momentum alignment. AM_20 at 3.8% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.06), momentum weakening. Elevated volume (1.6x 20MA), institutional activity likely. OFD pattern: -SUH (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.98% (CS: 68) | Neutral |
| RSI_14 | 63.1 | Neutral |
| MACD Histogram | -1.06 | Bearish |
| vs SMA20 | 1.038x | Above |
| vs SMA50 | 1.305x | Above |
| vs SMA200 | 2.469x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $70.81
- **Stop Loss:** $61.99 (12.5% risk)
- **Target:** $79.63 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 149
- **Position Value:** $10,550.69
- **Portfolio %:** 10.55%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-09 (Est: $-0.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $-0.18 | -14.4% |
| 2025Q2 | $-1.10 | $-1.26 | -14.4% |
| 2025Q1 | $-0.46 | $2.75 | +695.0% |
| 2024Q4 | $-0.72 | $-1.39 | -92.2% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_20*